Evaluation of ability of OR51T1 expression to predict primary hormone therapy efficacy among men with hormone-naive metastatic prostate cancer.

被引：0
|
作者：
Mochizuki, Taku
Miyoshi, Yasuhide
Kawahara, Takashi
Yokomizo, Yumiko
Hayashi, Narihiko
Yao, Masahiro
Miyamoto, Hiroshi
Uemura, Hiroji
机构：
[1] Yokohama City Univ Med Ctr, Yokohama, Kanagawa, Japan
[2] Yokohama City Univ Grad Sch Med, Yokohama, Kanagawa, Japan
[3] Johns Hopkins Sch Med, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.317
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
317
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Pilot study of an artificial intelligence-based deep learning algorithm to predict time to castration-resistant prostate cancer for metastatic hormone-naive prostate cancer
    Nakata, Wataru
    Mori, Hideo
    Tsujimura, Goh
    Tsujimoto, Yuichi
    Gotoh, Takayoshi
    Tsujihata, Masao
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (09) : 1062 - 1066
  • [32] Aggressive Variant Prostate Cancer in Men with Hormone Naive, de novo Metastatic Prostate Cancer (M1PC)
    Zhang, Miao
    Aparicio, Ana
    Wang, Xuemei
    Chapin, Brian F.
    Troncoso, Patricia
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 996 - 997
  • [33] Aggressive Variant Prostate Cancer in Men with Hormone Naive, de novo Metastatic Prostate Cancer (M1PC)
    Zhang, Miao
    Aparicio, Ana
    Wang, Xuemei
    Chapin, Brian F.
    Troncoso, Patricia
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 996 - 997
  • [34] Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis
    Ayer Botrel, Tobias Engel
    Clark, Otovio
    Lima Pompeo, Antonio Carlos
    Horta Bretas, Francisco Flavio
    Sadi, Marcus Vinicius
    Ferreira, Ubirajara
    dos Reis, Rodolfo Borges
    PLOS ONE, 2016, 11 (06):
  • [35] Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naive Prostate Cancer?
    Albiges, Laurence
    Loriot, Yohann
    Massard, Christophe
    Fizazi, Karim
    EUROPEAN UROLOGY, 2015, 68 (05) : 802 - 804
  • [36] BASELINE SERUM DEHYDROEPIANDROSTERONE SULFATE (DHEAS) CAN PREDICT RESPONSIVENESS TO PRIMARY ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH HORMONE NAIVE METASTATIC PROSTATE CANCER
    Yano, Akihiro
    Sugiyama, Hironori
    Cho, Eiken
    Takeshita, Hideki
    Okada, Yohei
    Morozumi, Makoto
    Kawakami, Satoru
    Yamada, Takumi
    JOURNAL OF UROLOGY, 2016, 195 (04): : E81 - E82
  • [37] Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naive bone-metastatic prostate cancer
    Ebbinge, Maria
    Berglund, Anders
    Section, Eberhard Varenhorst
    Hedlund, Per Olov
    Sandblom, Gabriel
    BJU INTERNATIONAL, 2018, 122 (04) : 583 - 591
  • [38] SINGLE INFUSION OF ZOLEDRONIC ACID TO PREVENT ANDROGEN-DEPRIVATION THERAPY-INDUCED BONE LOSS IN MEN WITH HORMONE-NAIVE PROSTATE CANCER
    Satoh, Takefumi
    Kimura, Masaki
    Matsumoto, Kazumasa
    Tabata, Ken-ichi
    Okusa, Hiroshi
    Bessho, Hideharu
    Matsuda, Daisuke
    Yamashita, Hideyuki
    Lwamura, Masatsugu
    Ishiyama, Hiromichi
    Hayakawa, Kazushige
    Baba, Shiro
    JOURNAL OF UROLOGY, 2009, 181 (04): : 230 - 231
  • [39] Efficacy and tolerance of treatments received beyond progression in men with metastatic hormone-naive prostate cancer treated with androgen deprivation therapy (ADT) with or without docetaxel in the GETUG-AFU 15 phase III trial.
    Lavaud, Pernelle
    Gravis, Gwenaelle
    Legoupil, Clemente
    Joly, Florence
    Oudard, Stephane
    Priou, Franck
    Mourey, Loic
    Soulie, Michel
    Latorzeff, Igor
    Delva, Remy
    Krakowski, Ivan
    Laguerre, Brigitte
    Theodore, Christine
    Ferrero, Jean Marc
    Beuzeboc, Philippe
    Habibian, Muriel
    Foulon, Stephanie
    Boher, Jean Marie
    Tergemina-Clain, Gabrielle
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naive metastatic prostate cancer patients - A propensity scoring approach
    Nagao, Kazuhiro
    Matsuyama, Hideyasu
    Nozawa, Masahiro
    Hara, Isao
    Nishioka, Tsukasa
    Komura, Takahiro
    Esa, Atsunobu
    Uejima, Shigeya
    Imanishi, Masaaki
    Uekado, Yasunari
    Ogawa, Takatoshi
    Kajikawa, Hiroshi
    Uemura, Hirotsugu
    ASIAN JOURNAL OF UROLOGY, 2016, 3 (01) : 33 - 38
12345